

## Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company's incentive program for the company's employees (Plan 2020/2024).

Today, the last trading day of the month, there are in total 265,144,687 shares and votes in Active Biotech.

**For further information, please contact:**

---

Helén Tuveßson, CEO, +46 46 19 21 56, [helen.tuveßson@activebiotech.com](mailto:helen.tuveßson@activebiotech.com)

Hans Kolam, CFO, +46 46 19 20 44, [hans.kolam@activebiotech.com](mailto:hans.kolam@activebiotech.com)

### About Active Biotech

---

**Active Biotech AB (publ) (NASDAQ Stockholm: ACTI)** is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.

*This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-03-31 08:30 CEST.*

### Attachments

---

## Number of shares and votes in Active Biotech